Literature DB >> 3002376

Partial purification of a 5.7K glycoprotein from bovine vitreous which inhibits both angiogenesis and collagenase activity.

C M Taylor, J B Weiss.   

Abstract

An inhibitor of angiogenic activity similar to that described by Raymond and Jacobson (1) has been partially purified and shown to be a glycoprotein of molecular mass 5,700. This inhibitor gave rise to an avascular zone on the chick vitelline plexus and also negated the action of a low Mr angiogenic factor. When the angiogenic inhibitor was incubated with mammalian collagenase it inhibited the enzyme activity by nearly 70%. The relevance of these findings to the role of collagenase in angiogenesis is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3002376     DOI: 10.1016/0006-291x(85)91222-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  Increased procollagenase activating angiogenic factor in the vitreous humour of oxygen treated kittens.

Authors:  C M Taylor; J B Weiss; B McLaughlin; R D Kissun; A Garner
Journal:  Br J Ophthalmol       Date:  1988-01       Impact factor: 4.638

3.  Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.

Authors:  S S Brem; D Zagzag; A M Tsanaclis; S Gately; M P Elkouby; S E Brien
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

4.  Proteomic analysis of the hyaloid vascular system regression during ocular development.

Authors:  Elena Albè; Jin-Hong Chang; Nathalie F Azar; Alexander R Ivanov; Dimitri T Azar
Journal:  J Proteome Res       Date:  2008-10-08       Impact factor: 4.466

5.  beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.

Authors:  B A Teicher; E A Sotomayor; Z D Huang; G Ara; S Holden; V Khandekar; Y N Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.

Authors:  E A Sotomayor; B A Teicher; G N Schwartz; S A Holden; K Menon; T S Herman; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.